Degradable hydrogel for retinal tamponade (phase 2)
Degradable hydrogel for retinal tamponade (phase 2)
批准号:
10219260
负责人:
Gavin James Braithwaite
金额:
$29.64万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-08-01 至 2022-07-31
关键词:
AddressAgeAlcoholsAnimalsBehaviorBlindnessCrosslinkerDataDeuterium OxideDevice RemovalDevicesEyeFormulationGasesGelGrantHydrogelsIn SituInferiorInflammationInflammatory ResponseInjectionsIntentionLeadLeftLiquid substanceMacular HoleMethodsModelingMolecular WeightOperative Surgical ProceduresOryctolagus cuniculusOutcomePatientsPerformancePhasePolymersPopulationPositioning AttributePostoperative PeriodProcessProne PositionPropertyProviderReactionRefractive IndicesRetinaRetinal DetachmentRetinal DiseasesRetinal PerforationsSafetySilicone OilsSystemTestingTimeValidationViscosityVitrectomyWorkanalytical methodbasebiomaterial compatibilitycrosslinkdesignefficacy studyefficacy testingethylene glycolexperienceexperimental studyhealingimprovedin vivomennovelphase 1 studypreclinical studypressureprogramsrepairedresponsesafety studyscreeningsexsmall moleculesuccess
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary
Retinal disorders are a common cause of debilitating vision loss. For many of these conditions,
including retinal detachments and macular holes, the only treatment is surgery. The first step of all
such surgeries is vitrectomy, the process of removing the vitreous gel through tiny ports in the front of
the eye. Each year, 1.1 million vitrectomies are performed globally with 300,000 performed in the US
alone, and in the majority of these cases a retinal tamponade is required to be left in the eye to
maintain pressure on the retina and aid healing. The global retinal tamponade market was recently
valued at USD $64.5 million in 2013 and is predicted to reach USD $77.5 million by 2020.
The current state of the art uses either an expansile gas, or a silicone oil to exert pressure on the
retina during healing (tamponade). However, neither method is ideal and therefore to address these
deficiencies, this phase 2 proposal extends early work we performed on a novel hydrogel that uses
two common synthetic biomedical polymers, namely a modified poly(vinyl alcohol) and poly(ethylene
glycol) in a form that creates a unique hydrogel system that is very low viscosity in liquid form but
then gels through crosslink formation in the eye. This formulation allows for injection through small
surgical ports followed by in vivo expansion resulting in 360-degree retinal tamponade. This unique
formulation will eliminate the need for post-operative patient positioning and will degrade to small
molecules that are readily cleared from the eye over the period of 3-5 weeks providing a temporary
tamponade force before degrading. Data from the Phase 1 supports that the resulting device will be
more patient friendly with almost no refractive issues and the ability for the patient to be fully mobile
and has proven degradation over 2-3 weeks with no inflammatory response, although this
degradation time is also tunable. In this Phase 2 we intend to refine the formulation for improved
performance and validate it within a relevant model to demonstrate efficacy.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Degradable hydrogel for retinal tamponade (phase 2)
-
批准号:9908974
-
项目类别:
-
资助金额:$29.61万
-
财政年份:2020
-
负责人:Gavin James Braithwaite
-
依托单位:
Degradable hydrogel for retinal tamponade
-
批准号:9255604
-
项目类别:
-
资助金额:$22.44万
-
财政年份:2017
-
负责人:Gavin James Braithwaite
-
依托单位:
Injectable, biocompatible poly (vinyl alcohol) hydrogels for tissue bulking
-
批准号:7747226
-
项目类别:
-
资助金额:$9.83万
-
财政年份:2009
-
负责人:Gavin James Braithwaite
-
依托单位:
An injectable biocompatible hydrogel nucleus pulposus replacement
-
批准号:7744555
-
项目类别:
-
资助金额:$7.67万
-
财政年份:2009
-
负责人:Gavin James Braithwaite
-
依托单位:
NOVEL, FAST, RELIABLE&INEXPENSIVE RADIATION DOSIMETER
-
批准号:6310476
-
项目类别:
-
资助金额:$9.86万
-
财政年份:2001
-
负责人:Gavin James Braithwaite
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: